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Allergen immunotherapy (AIT) is the practice of administering 
gradually increasing doses of the specific causative allergen to 
reduce the clinical reactivity of allergic subjects. A bulk of lit-
erature demonstrates that AIT is an effective and safe treatment 
to reduce allergic symptoms and the use of drugs. The preventive 
capacity of AIT is less investigated. The studies thus far avail-
able showed that this treatment, in both forms of subcutaneous 
immunotherapy (SCIT) and sublingual immunotherapy (SLIT) is 
able to prevent the development of asthma in patients with aller-
gic rhinitis and the occurrence of new sensitizations in patients 
monosensitized. Such outcomes demonstrate the ability of AIT to 
change the natural history of respiratory allergy. Of particular 
importance, SCIT with Hymenoptera venom has an invaluable 
role  in preventing potentially fatal anaphylactic reactions to 
the culprit sting in venom-allergic patients. Ongoing studies are 
aimed at evaluating the possible capacity of AIT in primary pre-
vention of allergy. All these capabilities are related to the mecha-
nisms of action of AIT. In fact, both SCIT and SLIT are able to 
modify the allergen presentation by dendritic cells that in turn 
modify the phenotype of allergen-specific T cells, switching from 
the Th2-type response, typical of allergic inflammation, to a Th1-
type response. An important role is played by allergen-specific 
T regulatory (Treg) cells, which produce suppressive cytokines 
such as IL-10 and TGF-beta. 
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Summary
Introduction
Allergen immunotherapy (AIT) is the practice of admin-
istering gradually increasing doses of the specific causa-
tive allergen to reduce the clinical reactivity of allergic 
subjects. As stated in the World Health Organization 
document dedicated to AIT, concerning the products 
to perform the treatment “The historical term allergen 
extract was changed to allergen vaccine to reflect the 
fact that allergen vaccines are used in medicine as im-
mune modifiers similarly to vaccines for infectious dis-
eases” [1]. AIT was introduced more than one century 
ago, but remained a merely empirical treatment until 
1954, when the first controlled trial was published, and 
was later continuously developed to reach full scientif-
ic evidence demonstrated by a number of meta-analy-
ses [2, 3]. The only method to administer AIT was the 
subcutaneous injection until the 1980s, when a series 
of fatal adverse reactions both in Europe [4] and in the 
USA [5] raised the important issue of treatment safety. 
The sublingual route, introduced by a trial based on very 
low doses [6] that now we know to be ineffective, has 
been subsequently the object of thorough investigation 
and has currently achieved full scientific evidence of ef-
ficacy [7-9].
Therefore, today two forms of AIT are available, subcu-
taneous immunotherapy (SCIT), which is the only treat-
ment recommended in patients with allergic reactions 
to Hymenoptera stings, and sublingual immunotherapy 
(SLIT) which is a valid option to treat patients with al-
lergic rhinitis and allergic asthma. A large literature is 
accessible evaluating the efficacy and safety of SCIT 
and SLIT, the aim of this article is to focus the preven-
tive capacity of both treatments.
Prevention of allergic reactions  
to Hymenoptera stings
Systemic reactions to insects belonging to the order of 
Hymenoptera, that include honeybees (Apis spp), bum-
blebees (Bombus spp), yellow jackets (Vespula spp), 
wasps (Polistes spp), and hornets (Vespa spp and Doli-
chovespula spp), affect about 3% of the general popula-
tion, with particular interest for anaphylaxis, that is as-
sociated to a risk of potentially fatal reactions [10]. SCIT 
with Hymenoptera venom, known as venom immuno-
therapy (VIT) is highly effective in preventing further 
systemic reactions [11] and is also very well tolerated, 
as showed by the absence (differently from SCIT with 
inhalant allergens) of fatal adverse reactions to VIT [12]. 
In particular, the capacity to prevent fatal reactions to 
stings is 100%, and the capacity to prevent any kind of 
systemic reactions is estimated in 90-95% [13]. Of note, 
the patients not completely protected from stings can 
achieve full protection by increasing the maintenance 
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dose over the recommended amount of 100 mcg, being 
possible to determine the protective dose in each indi-
vidual [14]. A recent important advance was represented 
by the recognition that VIT is effective and safe also in 
patients suffering from mastocytosis, which is a known 
risk factor for developing particularly severe reactions to 
insect stings [15, 16]. All these observations make VIT 
an invaluable treatment to prevent anaphylaxis from in-
sect stings.
Prevention of asthma in patients  
with allergic rhinitis
Allergic rhinitis and asthma are closely correlated and 
patients suffering only from rhinitis have a substantial 
risk to develop asthma [17]. A pivotal experience in 
demonstrating the ability of AIT to prevent such pro-
gression was the Preventive Allergy Treatment (PAT) 
study [18]. The PAT study evaluated a group of 183 
children, aged 6-14 years, with grass and/or birch pollen 
allergy after a 3-year course of SCIT, and found that the 
significant improvement in rhinitis symptoms observed 
at SCIT stopping persisted at a 5-year follow-up. The 
AIT treated children had, compared with control sub-
jects treated only with drugs, significantly less asthma 
after 5 years as evaluated by clinical symptoms. In addi-
tion, 147 children were followed-up 7 years after termi-
nation of AIT: the significant improvement in rhinocon-
junctivitis persisted at the follow-up, and significantly 
less actively treated subjects had developed asthma at 
the follow-up as evaluated by clinical symptoms. Pa-
tients who developed asthma among controls were 24/53 
while in the AIT group were 16/64 [19]. The longitudi-
nal treatment effect when adjusted for bronchial hyper-
responsiveness and asthma status at baseline including 
all observations at 3, 5 and 10 years time points was sta-
tistically significant (P = 0.0075). The odds ratio for no-
asthma was 4.6 (95% Confidence Interval [CI] 1.5-13.7) 
in favour of AIT. The authors concluded that AIT has 
long-term clinical effects and the potential of preventing 
development of asthma in children with allergic rhino-
conjunctivitis up to 7 years after treatment termination. 
There are also studies on prevention of asthma by SLIT. 
Di Rienzo et al. conducted a prospective parallel group 
study on 60 children (mean age 8.5 years) allergic to 
dust mites and divided into two matched groups: 35 un-
derwent a 4- to 5-year course of SLIT with standardized 
extract and 25 received only drug therapy [20]. The pa-
tients were evaluated at three time points (baseline, end 
of SLIT and 4 to 5 years after SLIT discontinuation) re-
garding presence of asthma and use of anti-asthma drugs. 
In the SLIT group significant differences were found for 
the presence of asthma (P </= 0.001) and the use of asth-
ma medications (P </= 0.01), whereas no difference was 
observed in the control group. Madonini et al showed in 
a retrospective survey on 302 patients treated with SLIT 
that, during a 1-year follow-up after stopping the treat-
ment only 1% of non-asthma patients reported an onset 
of respiratory symptoms. The clinical benefits were as-
sociated with the length of treatment: patients with long-
lasting benefits were treated for a mean duration of 29.1 
months, while patients showing a return to pre-SLIT 
condition were treated for a mean 13.3 months [21]. In 
a more recent study, 216 children with allergic rhinitis, 
with or without intermittent asthma, were evaluated and 
then randomized to receive drugs alone or drugs plus 
SLIT for 3 years; 144 children received SLIT and 72 
received only drugs. Asthma was less frequent in SLIT 
patients (odds ratio, 0.04; 95% confidence interval, 
0.01-0.17), and the number of children with a positive 
methacholine challenge result decreased significantly 
after 3 years only in the SLIT group [22]. 
Prevention of new sensitizazions
As reported above, the development of new sensitiza-
tions following the initial monosensitization is typical 
of the natural history of respiratory allergy. The issue of 
preventing new sensitizations by AIT was investigated 
in various studies. The first investigations concerned 
small populations of patients. Des Roches et al. stud-
ied 22 children monosensitized to dust mites receiving 
SCIT with standardized allergen extracts and 22 other 
age-matched controls. Children were followed-up for 3 
years, and it was found that 10 of the 22 children mono-
sensitized to dust mites treated with SIT did not have 
new sensitivities compared with 0 of 22 children in the 
control group, this difference being significant (p = 
0.001) [23]. In another small study, 23 patients allergic 
to grass pollen – 13 treated with SCIT and 10 controls – 
were prospectively followed for 6 years during the grass 
pollen season. At the last time point, 61% of the initially 
pollen-monosensitized children had developed new sen-
sitizations to perennial allergens compared to 100% in 
the control group [24]. The difference was significant 
(p < 0.05), but not so impressive as in the study by Des 
Roches. Of course, the modest number of patients make 
likely a stochastic distribution of data in such studies. 
A more robust study evaluated 134 children (age range 
5-8 years) with respiratory allergy due to monosensiti-
zation to mites, 75 treated with SCIT and 63 children 
treated with medication only, who were considered as 
controls. SCIT was administered for 3 years and all 
patients were followed-up for a total of 6 years. New 
sensitizations were assessed by skin prick test and se-
rum-specific IgE every year during the follow-up. At 
the end of the study, 69 SCIT treated and 54 controls 
were available; of them, 52 (75.4%) in the SCIT group 
showed no new sensitization, compared to 18 (33.3%) in 
the control group (p < 0.0002). The allergens most com-
mon responsible for the new sensitizations were pollens 
of Parietaria, grasses and olive [25].
A retrospective study evaluated a very large number of 
monosensitized patients, including 7182 patients treated 
with SCIT for 4 years and followed for further 3 years, 
and 1214 patients treated only with drugs for the same 
period years. All patients underwent prick test and spe-
cific IgE measurement before and after the 4 years of 
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SCIT and again 3 years later. The results showed that 
polysensitized subjects were 23.7% in SCIT-treated 
and 68% in drug treated after 4 years (P < 0.0001) and 
26.95% and 76.77%, respectively, after 7 years (p < 
0.0001). Asthmatic subjects were more prone to develop 
polysensitization in comparison to subjects suffering on-
ly from rhinitis (32.14% instead of 27.29% after 4 years, 
36.5% instead of 31.33% after 7 years; P < 0.0001) [26]. 
Concerning SLIT, in the previously cited study by Ma-
donini et al. on 302 patients followed-up for one year 
after stopping SLIT in only 9.6% of patients were de-
tected by skin tests new sensitizations [21]. In the study 
by Marogna et al. the rate of new sensitizations was even 
lower, corresponding to 3.1% of SLIT treated patients 
and to 34.8% of controls, with an odds ratio to develop 
new sensitization in controls equivalent to 16.85 [22]. 
In a further study, the same authors prospectively evalu-
ated the long-term effect of SLIT given for 3, 4, or 5 
years on 78 patients, 59 of whom completed the study, 
compared with 12 control subjects. The total duration 
of the follow-up was 15 years [27]. According to new 
sensitizations, all the control subjects over the 15 years 
period developed positive test to allergens previously 
negative, while this occurred in less than a quarter of 
the patients receiving SLIT (21% in treated for 3 years, 
12%, in treated for 4 years, and 11% in treated for 5 
years, respectively). 
Is AIT suitable for primary prevention  
of respiratory allergy?
The possibility to prevent the sensitization to inhalant 
allergens is currently under evaluation by Holt, who 
planned a prospective study of administration to new-
borns at risk of allergy (because of allergic parents) of 
sublingual extracts containing a mix of the most com-
monly sensitizing allergens [28]. The study is ongoing 
but a long time will be needed to achieve reliable obser-
vations on the real capacity to prevent, and not simply 
to postpone, the onset of allergy. It seems likely that the 
new method of AIT by intralymphatic injection, based 
on a very low number of administrations [29, 30], may 
represent in a near future a more suitable candidate 
method for primary prevention of allergy. 
The mechanisms underlying  
the preventive capacity of AIT 
The first mechanism suggested to explain the effective-
ness of AIT was the generation of IgG antibodies. As 
IgG induced by vaccination neutralize the infectious 
agents [31], IgG induced by AIT should block the con-
tact between the specific allergen and the IgE on the 
surface of mast cells and basophils [32, 33]. However, 
concerning prevention of anaphylaxis from insect stings, 
that is the most suitable model for a blocking role of 
IgG, a firm relationship between the amount of venom-
specific IgG and clinical protection was never achieved, 
especially in the long-term [34]. Thus, finer mechanisms 
are likely to be involved, such as the inhibition by IgG of 
effector cells activation through their FC-gamma recep-
tors [35]. In any case, the role of IgG antibodies should 
currently be viewed in the big picture of the effects of 
AIT on the immunologic response to the administered 
allergen, that seem similar in SCIT and SLIT [36-39]. In 
particular, the traditional, subcutaneous route of admin-
istration was first demonstrated to modify the allergen 
presentation by dendritic cells (DCs) that in turn modify 
the phenotype of allergen-specific T cells, switching 
from the Th2-type response, typical of allergic inflam-
mation and characterized by a cytokine pattern including 
IL-4, IL-5, IL-13, IL-17, and IL-32 to a Th1-type re-
sponse. This immune deviation is related to an increased 
IFN-gamma and IL-2 production as well as to the an-
ergy of Th2 or to tolerance, the latter being related to the 
generation of allergen-specific T regulatory (Treg) cells, 
which produce cytokines such as IL-10 and TGF-beta. 
Comparable immunologic changes, with a pivotal role 
for Dcs in the oral mucosa and IL-10 producing Tregs, 
were observed during SLIT with administration of high 
allergen doses [38].
Conclusions
AIT for respiratory allergy, in both forms of SCIT and 
SLIT, has showed, along with a clinical efficacy starting 
from a few months from initiation of treatment [1, 2, 7], a 
clear preventive capacity on the development of asthma 
in subjects with rhinitis and on appearance of new sen-
sitizations. This capacity is likely to be improved by the 
introduction of new materials to perform AIT. Valenta, 
who pioneered the diagnosis and treatment of allergy by 
using the molecular components of the allergens, sug-
gested that the availability of the structures of the most 
common allergen molecules allows currently to produce 
well-defined recombinant and synthetic allergy vac-
cines able to target more precisely the mechanisms of 
allergy, and offers new possible allergen-specific strate-
gies for prevention of allergic diseases [40]. However, 
to the purpose of preventing allergy in a child at risk it 
is strongly needed to increase the awareness on AIT in 
both the medical community and the lay, as currently 
conceived in international initiatives [41].
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